ENTOCORT (budesonide), locally acting corticosteroid

High clinical benefit in active microscopic colitis, but no demonstrated clinical benefit in the therapeutic strategy

• ENTOCORT has been granted marketing authorisation in remission induction treatment in patients suffering from active microscopic colitis.

• Its efficacy is suggested by data of poor methodological quality, particularly in lymphocytic colitis.

• It has not been compared to MIKICORT, another budesonide-based medicinal product having been granted marketing authorisation in collagenous colitis, or to other symptomatic treatments used off-label in practice (loperamide, 5 ASA, cholestyramine, etc.).